ATE292615T1 - Inhibitoren der durch alpha 4 vermittelten zelladhäsion - Google Patents

Inhibitoren der durch alpha 4 vermittelten zelladhäsion

Info

Publication number: ATE292615T1
Authority: AT; Austria
Prior art keywords: inhibitors; alpha; cell adhesion; mediated cell; mediated
Prior art date: 2000-08-31

Application number

AT01966246T

Other languages

English (en)

Inventor

Takayuki Kawaguchi

Sumihiro Nomura

Mikiko Tsukimoto

Toshiyuki Kume

Ila Sircar

Original Assignee

Tanabe Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2001-08-27

Publication date

2005-04-15

2001-08-27 Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co

2005-04-15 Application granted granted Critical

2005-04-15 Publication of ATE292615T1 publication Critical patent/ATE292615T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Psychology (AREA)

AT01966246T 2000-08-31 2001-08-27 Inhibitoren der durch alpha 4 vermittelten zelladhäsion ATE292615T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22912800P	2000-08-31	2000-08-31
PCT/US2001/026594 WO2002018320A2 (en)	2000-08-31	2001-08-27	INHIBITORS OF α4 MEDIATED CELL ADHESION

Publications (1)

Publication Number	Publication Date
ATE292615T1 true ATE292615T1 (de)	2005-04-15

Family

ID=22859926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01966246T ATE292615T1 (de)	2000-08-31	2001-08-27	Inhibitoren der durch alpha 4 vermittelten zelladhäsion

Country Status (28)

Country	Link
US (6)	US7026501B2 (de)
EP (1)	EP1315694B1 (de)
JP (1)	JP3899022B2 (de)
KR (1)	KR100528049B1 (de)
CN (1)	CN1229334C (de)
AR (1)	AR034556A1 (de)
AT (1)	ATE292615T1 (de)
AU (2)	AU2001286778B2 (de)
BR (1)	BR0113629A (de)
CA (1)	CA2418054C (de)
CZ (1)	CZ303460B6 (de)
DE (1)	DE60109943T2 (de)
DK (1)	DK1315694T3 (de)
ES (1)	ES2240509T3 (de)
HK (1)	HK1052684B (de)
HU (1)	HUP0302693A3 (de)
IL (2)	IL154305A0 (de)
MX (1)	MXPA03001837A (de)
MY (1)	MY129000A (de)
NO (1)	NO327861B1 (de)
NZ (1)	NZ524043A (de)
PL (1)	PL206656B1 (de)
PT (1)	PT1315694E (de)
RU (1)	RU2250895C2 (de)
SI (1)	SI1315694T1 (de)
TW (1)	TWI224587B (de)
WO (1)	WO2002018320A2 (de)
ZA (1)	ZA200301039B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE497385T1 (de)	2000-08-18	2011-02-15	Ajinomoto Kk	Neue phenylalanin-derivate
TWI312347B (en)	2001-02-08	2009-07-21	Eisai R&D Man Co Ltd	Bicyclic nitrogen-containing condensed ring compounds
PL214231B1 (pl)	2001-04-27	2013-07-31	Eisai R & D Man Co	Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
MY140707A (en) *	2002-02-28	2010-01-15	Mitsubishi Tanabe Pharma Corp	Process for preparing a phenylalanine derivative and intermediates thereof
US7122580B2 (en)	2002-08-09	2006-10-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
US7176216B2 (en)	2002-10-22	2007-02-13	Eisai Co., Ltd.	7-phenylpyrazolopyridine compounds
KR100984085B1 (ko) *	2002-10-22	2010-09-30	에자이 알앤드디 매니지먼트 가부시키가이샤	7-페닐 피라졸로피리딘 화합물
US7501538B2 (en)	2003-08-08	2009-03-10	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014533A2 (en) *	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions, and methods of use
EP1700850B1 (de)	2003-12-22	2015-07-15	Ajinomoto Co., Inc.	Phenylalaninderivat
US7410971B2 (en)	2003-12-26	2008-08-12	Eisai R&D Management Co., Ltd.	1,2-di(cyclic)substituted benzene compounds
MY140489A (en)	2003-12-26	2009-12-31	Eisai R&D Man Co Ltd	1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en)	2004-02-23	2008-09-02	Massachusetts Eye And Ear Infirmary	Treatment of ocular disorders
EP1832580A4 (de)	2004-12-20	2009-03-11	Eisai R&D Man Co Ltd	Kristall und salz von 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazin
DE602006019731D1 (de)	2005-06-09	2011-03-03	Ucb Pharma Sa	2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
EP2091916A2 (de) *	2005-11-23	2009-08-26	AstraZeneca AB	L-phenylalaninderivate und deren verwendung als integrinantagonisten
US7855291B2 (en)	2005-12-29	2010-12-21	Lexicon Pharmaceuticals, Inc.	Process for the preparation of substituted phenylalanines
EA019879B1 (ru)	2005-12-29	2014-07-30	Лексикон Фармасьютикалз, Инк.	Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
US7897763B2 (en)	2005-12-29	2011-03-01	Lexicon Pharmaceuticals, Inc.	Process for the preparation of substituted phenylalanines
IL172896A0 (en) *	2005-12-29	2006-06-11	Yeda Res & Dev	Cxcr4 inhibition
WO2007092471A2 (en) *	2006-02-03	2007-08-16	The Regents Of The University Of California	Methods for inhibition of lymphangiogenesis and tumor metastasis
JP2009526032A (ja) *	2006-02-09	2009-07-16	アストラゼネカアクチボラグ	化合物
HUE047230T2 (hu)	2006-02-28	2020-04-28	Biogen Ma Inc	Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
CA2641160A1 (en) *	2006-02-28	2007-09-07	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
AU2007224228B2 (en)	2006-03-03	2013-09-19	Biogen Ma Inc.	Methods of treating inflammatory and autoimmune diseases with natalizumab
AU2008293679B2 (en) *	2007-08-24	2013-09-12	Tersera Therapeutics Llc	Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
SI2266990T1 (sl)	2008-04-15	2013-01-31	Eisai R&D Management Co. Ltd.	Spojina 3-fenilpirazolo(5,1-b)tiazola
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
WO2011048091A1 (en) *	2009-10-21	2011-04-28	Glaxo Group Limited	Process for preparing a phenylalanine derivative
US11287423B2 (en)	2010-01-11	2022-03-29	Biogen Ma Inc.	Assay for JC virus antibodies
PT2524060T (pt)	2010-01-11	2018-03-28	Biogen Ma Inc	Ensaio para a deteção de anticorpos contra o vírus jc
PT3575792T (pt)	2011-05-31	2023-02-28	Biogen Ma Inc	Método de avaliação do risco de lmp
WO2013126595A1 (en) *	2012-02-21	2013-08-29	Massachusetts Eye And Ear Infirmary	Methods for treating corneal and conjunctival inflammation and inflammatory disorders
EP3004334A4 (de)	2013-05-28	2016-12-21	Biogen Ma Inc	Verfahren zur beurteilung eines pml-risikos
WO2018085552A1 (en) *	2016-11-02	2018-05-11	Saint Louis University	Integrin antagonists
KR102630416B1 (ko)	2018-10-30	2024-02-01	길리애드 사이언시즈, 인코포레이티드	알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en)	2018-10-30	2023-07-13	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
ES3013256T3 (en)	2018-10-30	2025-04-11	Gilead Sciences Inc	Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en)	2018-10-30	2021-11-23	Gilead Sciences, Inc.	Compounds for inhibition of α4β7 integrin
CN114222730B (zh)	2019-08-14	2024-09-10	吉利德科学公司	用于抑制α4β7整合素的化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK148576A (da)	1975-04-18	1976-10-19	Boehringer Mannheim Gmbh	Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
WO1995012611A1 (en)	1993-11-01	1995-05-11	Japat Ltd.	Endothelin receptor antagonists
EP0753004A1 (de)	1994-03-28	1997-01-15	Japat Ltd	Endothelin rezeptor antagoniste
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
JPH11505522A (ja)	1995-04-21	1999-05-21	ノバルティス・アクチエンゲゼルシャフト	エンドセリン阻害剤としてのｎ−アロイルアミノ酸アミド
EP1001764A4 (de)	1997-05-29	2005-08-24	Merck & Co Inc	Heterozyklische amide als zelladhäsionshemmern
DE69833654T2 (de)	1997-05-29	2006-12-14	Merck & Co., Inc. (A New Jersey Corp.)	Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
AU728435B2 (en)	1997-05-29	2001-01-11	Merck & Co., Inc.	Sulfonamides as cell adhesion inhibitors
DE69820614T2 (de)	1997-05-30	2004-09-30	Celltech Therapeutics Ltd., Slough	Entzündungshemmende tyrosin-derivate
DK0991619T3 (da)	1997-06-23	2003-12-29	Tanabe Seiyaku Co	Inhibitorer af alfa 4-beta 1-medieret celleadhæsion
NZ502582A (en)	1997-07-31	2002-07-26	American Home Prod	Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1001974B1 (de)	1997-07-31	2006-05-24	Elan Pharmaceuticals, Inc.	Verbindungen mit einer 4-amino-phenylalaningruppe, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
KR20010022412A (ko)	1997-07-31	2001-03-15	진 엠. 듀발	Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩티드 화합물
AR016133A1 (es)	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
CN1265669A (zh)	1997-07-31	2000-09-06	伊兰药品公司	抑制由vla－4介导的白细胞粘着的化合物
HUP0003921A3 (en)	1997-07-31	2001-03-28	Wyeth Corp	Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
BR9812111A (pt)	1997-07-31	2000-07-18	Elan Pharm Inc	Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4
HUP0002680A3 (en)	1997-07-31	2001-12-28	American Home Prod	Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
ATE267801T1 (de)	1997-08-22	2004-06-15	Hoffmann La Roche	N-alkanoylphenylalaninderivate
DE69821950T2 (de)	1997-08-22	2004-12-16	F. Hoffmann-La Roche Ag	N-aroylphenylalaninderivate
US6191171B1 (en) *	1997-11-20	2001-02-20	Merck & Co., Inc.	Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en)	1997-11-21	1999-06-03	Merck & Co., Inc.	Substituted pyrrole derivatives as cell adhesion inhibitors
ES2221227T3 (es)	1997-11-24	2004-12-16	MERCK & CO., INC.	Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
US6271252B1 (en)	1997-11-24	2001-08-07	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
US6197794B1 (en)	1998-01-08	2001-03-06	Celltech Therapeutics Limited	Phenylalanine derivatives
MY153569A (en) *	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en)	1998-01-27	2001-12-11	Celltech Therapeutics Limited	Phenylalanine derivatives
ATE273273T1 (de) *	1998-02-26	2004-08-15	Celltech Therapeutics Ltd	Phenylalaninderivate als inhibitoren von alpha4 integrinen
US6521626B1 (en)	1998-03-24	2003-02-18	Celltech R&D Limited	Thiocarboxamide derivatives
GB9811159D0 (en)	1998-05-22	1998-07-22	Celltech Therapeutics Ltd	Chemical compounds
GB9812088D0 (en)	1998-06-05	1998-08-05	Celltech Therapeutics Ltd	Chemical compounds
AU8059598A (en)	1998-06-11	1999-12-30	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en)	1998-06-23	2004-06-11	Upjohn Co	Inhibitors of alpha4beta1 mediated cell adhesion
EP1144365B1 (de)	1998-12-22	2004-03-17	Tanabe Seiyaku Co., Ltd.	Inhibitoren der alpha-4 beta-1 vermittelten zelladhäsion
GB2354440A (en)	1999-07-20	2001-03-28	Merck & Co Inc	Aryl amides as cell adhesion inhibitors
AU6903200A (en) *	1999-08-16	2001-03-13	Merck & Co., Inc.	Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) *	1999-08-20	2001-03-19	Merck & Co., Inc.	Substituted ureas as cell adhesion inhibitors
ATE364592T1 (de) *	1999-09-24	2007-07-15	Genentech Inc	Tyrosinderivate
US20040198833A1 (en)	2000-08-31	2004-10-07	Bender David Michael	Acetylenic sulfonamide derivatives

2001
- 2001-08-21 MY MYPI20013917A patent/MY129000A/en unknown
- 2001-08-27 MX MXPA03001837A patent/MXPA03001837A/es active IP Right Grant
- 2001-08-27 CZ CZ20030487A patent/CZ303460B6/cs not_active IP Right Cessation
- 2001-08-27 CA CA 2418054 patent/CA2418054C/en not_active Expired - Fee Related
- 2001-08-27 NZ NZ524043A patent/NZ524043A/en not_active IP Right Cessation
- 2001-08-27 ES ES01966246T patent/ES2240509T3/es not_active Expired - Lifetime
- 2001-08-27 PL PL365668A patent/PL206656B1/pl unknown
- 2001-08-27 AT AT01966246T patent/ATE292615T1/de active
- 2001-08-27 CN CNB018149871A patent/CN1229334C/zh not_active Expired - Fee Related
- 2001-08-27 EP EP01966246A patent/EP1315694B1/de not_active Expired - Lifetime
- 2001-08-27 HK HK03105043.3A patent/HK1052684B/en not_active IP Right Cessation
- 2001-08-27 AU AU2001286778A patent/AU2001286778B2/en not_active Ceased
- 2001-08-27 RU RU2003105885/04A patent/RU2250895C2/ru not_active IP Right Cessation
- 2001-08-27 US US10/333,985 patent/US7026501B2/en not_active Expired - Fee Related
- 2001-08-27 AU AU8677801A patent/AU8677801A/xx active Pending
- 2001-08-27 BR BR0113629-1A patent/BR0113629A/pt active Search and Examination
- 2001-08-27 SI SI200130351T patent/SI1315694T1/xx unknown
- 2001-08-27 HU HU0302693A patent/HUP0302693A3/hu unknown
- 2001-08-27 DE DE60109943T patent/DE60109943T2/de not_active Expired - Lifetime
- 2001-08-27 DK DK01966246T patent/DK1315694T3/da active
- 2001-08-27 KR KR10-2003-7001993A patent/KR100528049B1/ko not_active Expired - Fee Related
- 2001-08-27 WO PCT/US2001/026594 patent/WO2002018320A2/en not_active Ceased
- 2001-08-27 PT PT01966246T patent/PT1315694E/pt unknown
- 2001-08-27 ZA ZA200301039A patent/ZA200301039B/xx unknown
- 2001-08-27 IL IL15430501A patent/IL154305A0/xx unknown
- 2001-08-27 JP JP2002523438A patent/JP3899022B2/ja not_active Expired - Fee Related
- 2001-08-31 TW TW090121581A patent/TWI224587B/zh not_active IP Right Cessation
- 2001-08-31 AR ARP010104172A patent/AR034556A1/es active IP Right Grant
2003
- 2003-02-05 IL IL154305A patent/IL154305A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030885A patent/NO327861B1/no not_active IP Right Cessation
2005
- 2005-07-13 US US11/179,729 patent/US7456217B2/en not_active Expired - Fee Related
2008
- 2008-10-07 US US12/247,129 patent/US7671090B2/en not_active Expired - Fee Related
2010
- 2010-01-07 US US12/683,648 patent/US7872151B2/en not_active Expired - Fee Related
- 2010-12-08 US US12/962,707 patent/US8501809B2/en not_active Expired - Fee Related
2013
- 2013-07-03 US US13/934,405 patent/US20130289109A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL206656B1 (pl)	2010-09-30
EP1315694A2 (de)	2003-06-04
HK1052684A1 (en)	2003-09-26
NO20030885D0 (no)	2003-02-25
HUP0302693A3 (en)	2005-05-30
CZ2003487A3 (cs)	2003-06-18
US7872151B2 (en)	2011-01-18
AU8677801A (en)	2002-03-13
WO2002018320A3 (en)	2002-06-06
HUP0302693A2 (hu)	2003-12-29
CA2418054A1 (en)	2002-03-07
US7456217B2 (en)	2008-11-25
US20100113820A1 (en)	2010-05-06
WO2002018320A2 (en)	2002-03-07
EP1315694B1 (de)	2005-04-06
US20130289109A1 (en)	2013-10-31
CN1449377A (zh)	2003-10-15
PT1315694E (pt)	2005-07-29
AU2001286778B2 (en)	2005-02-10
DK1315694T3 (da)	2005-08-08
CZ303460B6 (cs)	2012-09-26
US7671090B2 (en)	2010-03-02
MXPA03001837A (es)	2003-10-15
CA2418054C (en)	2008-08-05
DE60109943D1 (de)	2005-05-12
IL154305A0 (en)	2003-09-17
KR100528049B1 (ko)	2005-11-15
US20030176498A1 (en)	2003-09-18
PL365668A1 (en)	2005-01-10
NO20030885L (no)	2003-02-25
CN1229334C (zh)	2005-11-30
BR0113629A (pt)	2003-07-22
JP2004507519A (ja)	2004-03-11
KR20030059099A (ko)	2003-07-07
HK1052684B (en)	2005-07-22
SI1315694T1 (en)	2005-10-31
NZ524043A (en)	2004-08-27
US8501809B2 (en)	2013-08-06
AR034556A1 (es)	2004-03-03
ZA200301039B (en)	2004-02-09
US7026501B2 (en)	2006-04-11
IL154305A (en)	2010-11-30
MY129000A (en)	2007-03-30
JP3899022B2 (ja)	2007-03-28
RU2250895C2 (ru)	2005-04-27
DE60109943T2 (de)	2006-02-09
US20090111879A1 (en)	2009-04-30
US20050282900A1 (en)	2005-12-22
ES2240509T3 (es)	2005-10-16
TWI224587B (en)	2004-12-01
NO327861B1 (no)	2009-10-05
US20110077299A1 (en)	2011-03-31

Legal Events

Date

Code

Title

Description

2005-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1315694

Country of ref document: EP

Publication	Publication Date	Title
DE60109943D1 (de)	2005-05-12	Inhibitoren der durch alpha 4 vermittelten zelladhäsion
DK1049662T3 (da)	2006-10-23	Inhibitorer af alpha4-medieret celleadhæsion
DK0842944T3 (da)	2003-10-27	Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4
DK0842945T3 (da)	2003-06-10	Heterocykliske forbindelser som inhibitorer af leukocytadhæsionen og VLA-4-antagonister
EP1507541A4 (de)	2009-06-03	Hemmer und anwendungsverfahren dafür
DK0842943T3 (da)	2003-06-02	5-Ring-heterocykliske forbindelser som inhibitorer af leukocytadhæsion og som VLA-4-antagonister
DE60317564D1 (de)	2007-12-27	Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
NO20003808D0 (no)	2000-07-25	Substituerte oksoazaheterosyklylfaktor Xa inhibitorer
DK1064298T3 (da)	2009-01-19	Inhibitorer af caspaser
DK1077943T3 (da)	2009-03-16	Heterocykliske inhibitorer af p38
ID19198A (id)	1998-06-28	Inhibitor metaloprotease heterosiklik
DK1114051T3 (da)	2003-07-14	Inhibitorer for p38
FI973360A0 (fi)	1997-08-15	Uusia dipeptidisiä amidiineja trombiininestäjiksi
DK1150982T3 (da)	2005-12-27	Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
DE69637328D1 (de)	2008-01-03	Zelladhäsionsinhibitoren
ATE460424T1 (de)	2010-03-15	Factor viia inhibitore
EP1691812A4 (de)	2010-01-13	Gtpase-hemmer und anwendungsverfahren
ATE277023T1 (de)	2004-10-15	Indanderivate und ihre verwendung als zelladhäsionsinihibitoren
PT1189929E (pt)	2003-12-31	Inibidores do factor viia
ATE411995T1 (de)	2008-11-15	Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion
DK1130214T3 (da)	2005-08-29	Korrosionsinhibitorer
NO20013669D0 (no)	2001-07-26	Reverse hydroksamatinhibitorer av matriks metalloproteinaser
EP1222308A4 (de)	2005-02-16	Inhibitoren der antiprotozoalen histonazyltransferase
PL366012A1 (pl)	2005-01-24	Kompozycja i sposób oznaczania glikozydazy
DK1307455T3 (da)	2005-07-25	Inhibitorer af alpha-L-beta-2-medieret celleadhæsion